Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Orally active iron chelators in development at Novartis

Feb. 16, 1998

TheraTech and SmithKline Beecham join forces on nicotine product

Feb. 3, 1998

Dual 5-HT reuptake inhibitors/5-HT1A antagonists developed at Lilly

Jan. 26, 1998

New chelating agent developed by Israeli researchers

Jan. 21, 1998

U.K. launch for inhaled nicotine replacement therapy

Dec. 23, 1997

Antizol cleared by FDA as first antidote for ethylene glycol poisoning

Dec. 19, 1997

U. of Florida prepares new metal chelators

Dec. 18, 1997

AMPA antagonist investigated for treatment of drug withdrawal

Dec. 9, 1997

FDA clears IND for ImmuLogic's cocaine vaccine

Dec. 5, 1997

Alza and SmithKline Beecham expand Nicoderm marketing agreement

Nov. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.